Direct pharmaceutical supply with complete HPLC purity profiles, mass spectrometry verification, and end-to-end technical documentation.
Understanding the chemical synthesis challenges, conformational stability, and cellular signaling networks of the foundational Mitochondrial-Derived Peptide (MDP).
Humanin is a 24-amino-acid peptide encoded within the 16S ribosomal RNA gene of the mitochondrial genome (Sequence: Met-Ala-Pro-Arg-Gly-Phe-Ser-Cys-Leu-Leu-Leu-Leu-Thr-Ser-Glu-Ile-Asp-Leu-Pro-Val-Lys-Arg-Arg-Ala). With a monoisotopic molecular weight of 2687.24 Da, its chemical synthesis requires precise management of the highly hydrophobic central core consisting of four sequential leucine residues (Leu9-Leu12), which frequently induces on-resin steric β-sheet aggregation during solid-phase elongation.
To overcome the natural degradation kinetics and enhance biological potency, medicinal chemists substitute Serine-14 with Glycine, generating [Gly14]-Humanin (HNG). This single amino acid alteration induces an approximate 1,000-fold increase in cytoprotective and neuroprotective efficacy against amyloid-beta toxicity, hypoxia, and endoplasmic reticulum (ER) stress. Industrial manufacturers must control diastereomeric integrity (D-amino acid limits <0.15%) to maintain reproducible receptor affinity across batches.
Humanin exerts biological cytoprotection through dual pathways: extracellular binding to a heterotrimeric receptor complex (comprising gp130, WSX-1, and CNTFRα) as well as the G-protein-coupled formyl peptide receptor-like 1 (FPRL-1 / FPR2), leading to STAT3 phosphorylation. Concurrently, intracellular Humanin directly binds and neutralizes pro-apoptotic Bax and Bid, preventing mitochondrial outer membrane permeabilization (MOMP) and suppressing caspase-dependent apoptosis cascade execution.
Commercial guide for analytical standards, research-grade lots, and pilot-to-commercial cGMP bulk manufacturing campaigns.
| Peptide Variant / Sequence | Purity Grade | Batch Scale | Counter-Ion | Indicative Price Range (USD) | Lead Time & Release CoA |
|---|---|---|---|---|---|
| Native Humanin (HN-24) Met-Ala-Pro-Arg-Gly...-Ala |
≥ 95.0% HPLC | 10 mg – 50 mg | TFA (Trifluoroacetate) | $180 – $380 / vial | 5 – 7 Business Days (HPLC, MS) |
| Native Humanin (HN-24) Bulk Research Grade |
≥ 98.0% HPLC | 1 g – 10 g | TFA or Acetate | $1,200 – $2,400 / gram | 2 – 3 Weeks (Complete CoA, KF) |
| [Gly14]-Humanin (HNG) High-Potency Longevity Lead |
≥ 98.5% HPLC | 500 mg – 5 g | Acetate (Pharmaceutical) | $1,450 – $2,850 / gram | 2 Weeks (HPLC, MS, AAA, Endotoxin) |
| Biotinylated / FITC-Labeled HNG Fluorescent/Receptor Affinity Probe |
≥ 95.0% HPLC | 10 mg – 100 mg | TFA | $450 – $1,100 / lot | 10 – 14 Business Days (Full Trace) |
| cGMP-Grade Humanin / HNG IND-Enabling / Clinical Pilot |
≥ 99.0% HPLC | 100 g – 1 kg+ | Acetate / Sterile Lyophilized | Project Quoted (Custom CDMO) | 6 – 10 Weeks (ICH Q7 Process, DMF) |
Synthesis yields are heavily impacted by the central -Leu-Leu-Leu-Leu- (residues 9-12) sequence. Solvation crashes on standard polystyrene resins require specialized PEG-based matrices (such as ChemMatrix) and pseudoproline or Dmb dipeptide building blocks, incrementally increasing raw material inputs while securing ultra-pure monomeric output.
While standard solid-phase cleavage yields trifluoroacetate (TFA) salts, in-vivo translational protocols and clinical formulations mandate acetate or hydrochloride exchange. Efficient ion-exchange chromatography adds approximately 15% to 25% processing costs but prevents TFA-induced cellular cytotoxicity and respiration artifacts.
Due to the sensitivity of methionine (Met1) and cysteine (Cys8) to oxidative conversion (Met-sulfoxide and inter-chain disulfide dimer artifacts), controlled lyophilization under nitrogen blanket protection is required. Moving from gram to kilogram scale reduces per-unit lyophilization overhead by up to 58%.
How upstream chemical integration, high-capacity automated reactors, and engineering depth deliver unmatched stability to global pharmaceutical supply networks.
Chinese facilities sit at the source of global amino acid manufacturing. High-purity Fmoc-protected amino acids, coupling reagents (HBTU, HATU, PyBOP, OxymaPure), and specialized cleavage scavengers are synthesized in-country, insulating overseas buyers from intermediate shortages and fluctuating import tariffs.
Modern synthesis facilities in bio-clusters such as Hangzhou and Jiangsu maintain industrial microwave-assisted peptide reactors and large-bore solid-phase synthesis vessels (ranging from 50L to 1000L). This enables multi-kilogram Humanin campaigns per run, ensuring unmatched batch-to-batch homogeneity.
Purification of complex sequences containing hydrophobic clusters requires cutting-edge Dynamic Axial Compression (DAC) HPLC systems (up to 600mm ID). Chinese CDMOs deploy continuous preparatory reverse-phase chromatography, systematically achieving purity levels >98.5% with high recovery yields.
By coupling capital efficiency with seasoned chemical engineering teams possessing decades of peptide process development experience, Chinese CDMO manufacturers deliver a 30% to 50% overall cost advantage on Humanin APIs relative to North American or European custom synthesis providers.
Strategic sourcing channels: Who is buying Humanin, what specifications do they require, and how do enterprise procurement workflows function?
Translational anti-aging biotechnology ventures represent the fastest-growing buyer segment. Sourcing managers in the US, Switzerland, and the UK require multi-gram batches of high-purity [Gly14]-Humanin (HNG) for rodent longevity intervention programs, cellular senescence reversal assays, and mitochondrial bioenergetics restoration studies.
Pharma sponsors conducting preclinical studies for Alzheimer's disease (AD), Amyotrophic Lateral Sclerosis (ALS), and Parkinson's disease target Humanin's unique property of rescuing primary neurons from amyloid-beta (Aβ1-42) and familial AD gene insults. Sourcing needs focus on strict endotoxin limits (<5 EU/mg) and verified counter-ion profiles.
Premium skincare formulation labs in East Asia and Europe actively evaluate Humanin derivatives as next-generation signal peptides. These buyers require multi-kilogram commercial capacity, comprehensive cosmetic safety dossiers, stability in topical emulsion vehicles, and competitive gram-level pricing structures.
Exploring the cellular mechanisms, target tissues, and therapeutic validation pathways driving experimental interest in HN and its synthetic variants.
Preclinical cardiac injury models demonstrate that systemic HNG administration during acute myocardial infarction markedly reduces infarct volume. By interacting with the mitochondrial permeability transition pore (mPTP) and activating the SAFE (Survivor Activating Factor Enhancement) pathway, Humanin preserves cardiomyocyte viability and attenuates post-ischemic remodeling.
Humanin acts in the hypothalamus to activate central STAT3, subsequently suppressing hepatic glucose production and normalizing peripheral glucose disposal. In translational models of type 2 diabetes and metabolic dysfunction-associated steatohepatitis (MASH), Humanin administration restores insulin sensitivity and curtails visceral adipose inflammation.
Retinal Pigment Epithelium (RPE) cells exposed to chronic oxidative stress and lipofuscin accumulation mimic the cellular environment of Age-Related Macular Degeneration (AMD). Exogenous Humanin enters RPE cells via receptor-mediated endocytosis, upregulates mitochondrial biogenesis factors (PGC-1α, TFAM), and suppresses cell death induced by chemical oxidants.
Preclinical oncological models indicate that Humanin can selectively shield normal somatic tissues—including male germ cells, peripheral sensory nerves, and renal tubule epithelia—from cytotoxic insults (e.g., cisplatin, bortezomib) without impairing the anti-neoplastic efficacy of the primary chemotherapeutic agents.
Strict international standards alignment: Bridging Chinese factory production with FDA, EMA, PMDA, and NMPA regulatory frameworks.
Every commercial batch is accompanied by comprehensive analytical release documentation: ultra-high performance liquid chromatography (UHPLC) purity chromatograms, high-resolution electrospray ionization mass spectrometry (ESI-HRMS), amino acid analysis (AAA) for exact peptide content quantification, Karl Fischer coulometric titration for residual moisture, and residual solvent profiling by headspace gas chromatography (HS-GC).
For biopharmaceutical enterprises advancing toward Investigational New Drug (IND) or Clinical Trial Authorisation (CTA) filings, dedicated regulatory affairs desks compile Chemistry, Manufacturing, and Controls (CMC) packages. This includes Type II Drug Master Files (DMF) for the US FDA and Active Substance Master Files (ASMF) for EMA submissions, covering synthetic route validation and critical process parameters (CPPs).
Peptide APIs are temperature-sensitive biomolecules requiring rigorous physical safeguards. Export desks manage temperature-monitored cold-chain shipping (-20°C with validated real-time data loggers) through established international hubs. Seamless customs documentation, HS classification guidance (HS 2937.19), and non-hazardous certification guarantee rapid customs clearance across North America, Europe, and Asia.
From computational sequence design to lipid conjugation: How the peptide industry is unlocking next-generation pharmacokinetics for Humanin derivatives.
Unmodified native Humanin suffers from a relatively short circulating half-life in human plasma (under 30 minutes) due to rapid proteolytic degradation by neutral endopeptidases. Manufacturers are engineering long-acting derivatives through site-specific PEGylation, fatty acid acylation (C16-C20 diacid conjugation analogous to semaglutide architectures), and D-amino acid retro-inverso peptide scanning.
Generative protein language models and structural prediction tools (AlphaFold-Multimer) are being actively deployed to map Humanin's low-affinity conformational states when docking to the gp130/WSX-1/CNTFR complex. This enables CDMOs to rapidly screen and custom-synthesize second-generation MDP mimetics with nanomolar binding affinity and enhanced stability.
Driven by global sustainability initiatives, top-tier Chinese peptide synthesis facilities are transitioning away from hazardous polar aprotic solvents such as DMF and NMP. Adoption of green solvents—including Cyrene, 2-MeTHF, and water-based micellar peptide coupling technologies—drastically reduces E-factor metrics in multi-kilogram Humanin manufacturing campaigns.
Essential technical, analytical, and supply chain answers for pharmaceutical procurement specialists and laboratory researchers.
Native Humanin is the endogenous 24-amino-acid mitochondrial peptide containing Serine at position 14. [Gly14]-Humanin (HNG) is a synthetic derivative where Serine-14 is substituted by Glycine. This single residue replacement stabilizes the peptide against proteolytic degradation and increases neuroprotective potency by approximately 1,000 times in preclinical Alzheimer's and ischemia assays.
Standard synthetic peptides are cleaved using trifluoroacetic acid (TFA), leaving residual TFA counter-ions. In cellular assays and animal studies, TFA can inhibit cell proliferation, impair mitochondrial respiration, and induce false-positive toxicity. For in-vivo and clinical research, buyers should explicitly specify acetate or hydrochloride counter-ion exchange (TFA < 0.5%).
The sequence of four consecutive leucines forms strong intermolecular beta-sheet aggregates during SPPS elongation, which can lead to incomplete coupling and truncated deletion peptides (des-Leu impurities). To achieve purity levels exceeding 98%, manufacturers utilize elevated temperature coupling, pseudoproline dipeptides, and extended deprotection protocols, necessitating 2 to 3 weeks of standard synthesis time.
A rigorous pharmaceutical CoA must document: HPLC monomeric purity (typically ≥95% to ≥98.5%), mass confirmation by ESI-MS or MALDI-TOF, Net Peptide Content (via Amino Acid Analysis), residual water content (Karl Fischer), counter-ion percentage, bacterial endotoxin content (LAL assay, <10 EU/mg), and residual organic solvents (HS-GC).
Humanin contains an N-terminal Methionine (Met1) and Cysteine (Cys8), making it susceptible to sulfoxide oxidation and dimer formation. Lyophilized peptides should be stored sealed under inert gas (argon or nitrogen) at -20°C (or -80°C for multi-year preservation). Once reconstituted in sterile water or buffered saline, solutions should be aliquoted and kept frozen to avoid repeated freeze-thaw cycles.
Yes. Leading Chinese peptide manufacturers maintain state-of-the-art facilities compliant with ICH Q7 guidelines. Dedicated project management teams support process validation, critical impurity profiling, ICH stability testing, and the generation of complete Drug Master Files (DMF) for seamless submission to the US FDA, EMA, and other regulatory bodies.
Browse additional high-demand synthetic peptides, GLP-1/glucagon receptor dual agonists, and neuro-endocrine APIs available for commercial synthesis.
Thin
